A Severe Mouse Model of Alpha-Thalassemia to Study Abnormal Iron Metabolism and Erythropoiesis, Hematopoietic Stem Cell Behavior and Development of a Gene Therapy Approach for Its Treatment
Maxwell Chappell(Children's Hospital of Philadelphia), Stefano Rivella(Children's Hospital of Philadelphia), Amaliris Guerra(Children's Hospital of Philadelphia), Stavros Glentis, Valentina Ghiaccio(Children's Hospital of Philadelphia), Antonis Kattamis, Michael Triebwasser(University of Michigan), Osheiza Abdulmalik(Children's Hospital of Philadelphia), Laura Breda(Children's Hospital of Philadelphia), Kandace Gollomp(Children's Hospital of Philadelphia), Megan Fedorky(Children's Hospital of Philadelphia), Nattiya Teawtrakul(Khon Kaen University), Danuta Jarocha(Jagiellonian University)
Cited by 1
Related Papers
In vivo hematopoietic stem cell modification by mRNA delivery
|Science|2023|321
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells<sup>†,‡</sup>
|British Journal of Haematology|2005|244